Cargando…
Natriuretic Peptide-Based Novel Therapeutics: Long Journeys of Drug Developments Optimized for Disease States
SIMPLE SUMMARY: Natriuretic peptides are endogenous hormones produced in the heart and vascular endothelium, and they enable cardiorenal protective actions or bone growth via cGMP stimulation through their receptor guanylyl cyclase receptor A or B. To optimize the drug for each disease state, we mus...
Autores principales: | Ichiki, Tomoko, Jinno, Atsushi, Tsuji, Yoshihisa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9219923/ https://www.ncbi.nlm.nih.gov/pubmed/35741380 http://dx.doi.org/10.3390/biology11060859 |
Ejemplares similares
-
M-atrial natriuretic peptide and nitroglycerin in experimental acute hypertensive heart failure: differential actions of two cGMP activating therapeutics
por: McKie, Paul M, et al.
Publicado: (2013) -
A novel designer natriuretic peptide CD-NP suppresses TGF-beta 1 induced collagen Type I production in human cardiac fibroblasts
por: Ichiki, Tomoko, et al.
Publicado: (2009) -
M‐Atrial Natriuretic Peptide and Nitroglycerin in a Canine Model of Experimental Acute Hypertensive Heart Failure: Differential Actions of 2 cGMP Activating Therapeutics
por: McKie, Paul M., et al.
Publicado: (2014) -
Natriuretic peptides: Diagnostic and therapeutic use
por: Pandit, Kaushik, et al.
Publicado: (2011) -
Chronic natriuretic peptide protein therapeutics
por: Chen, Horng H, et al.
Publicado: (2013)